Diana Zuckerman spoke on behalf of NCHR and CPTF at Oct 2025 FDA Tobacco Advisory Committee TPSAC meeting on whether Phillip Morris heat sticks and other IQOS products should continue to be marketed as low risk. We pointed out that these products have evidence of substantial risks in the short-term and long-term risks are likely to be greater.
Read More »On Medical Treatments & Products
Oral Testimony of Dr. Diana M. Zuckerman, Examining Policies to Enhance Seniors’ Access to Breakthrough Medical Technologies
September 18, 2025, House Energy & Commerce Committee: Dr Diana Zuckerman testified about why Medicare should not be required to pay for all Breakthrough medical devices and multi-cancer diagnostic tests unless they are proven safe, effective, reasonable, and necessary for Medicare age patients.
Read More »Testimony of Dr. Diana Zuckerman at the FDA Plastic Surgery Advisory Panel Meeting On Dermal Fillers for the Decolletage Area
August 13, 2025: Diana Zuckerman testified at the FDA panel meeting about the risks of dermal filler for decolletage. Known risks include pain, lumps, rashes, stroke, and interference with breast cancer screening. We explained that patients and their physicians need specific information about the frequency of these risks so that they can make informed decisions about whether they want this cosmetic procedure.
Read More »NCHR Comment on Hernia Mesh Package Labeling Recommendations
Why are there tens of thousands of reports to FDA of patients harmed by mesh used in hernia repair? NCHR points out that the FDA proposed guidance is unlikely to reduce that harm because it does not point out the many serious risks of mesh. We tell the FDA that mesh labeling should have warnings about frequency of the many adverse events of specific mesh products, and FDA should require research to determine which products are safer and which are more dangerous, and for which patients.
Only social media should be: X/Blueky: Why have tens of thousands of patients been harmed by mesh used in hernia repair? FDA’s proposed solution will not solve the problem of dangerous mesh complications.
NCHR Testimony FDA Advisory Committee on Oncological Drugs on Benrep for Multiple Myeloma
July 17, 2025: Dr. Diana Zuckerman testifies for NCHR about GSK study flaws of Benrep at FDA Oncology Drugs Advisory Committee. The very high risks of ocular toxicity outweighs the benefits and other better treatments are available.
Read More »